Medtronic unveils results from first-in-human study for EV ICD systems
Category: #health  By Saipriya Iyer  Date: 2019-05-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Medtronic unveils results from first-in-human study for EV ICD systems

Medtronic plc has reportedly unveiled the results from a test study of its investigational extravascular ICD system, where a lead is positioned outside of the heart and veins to provide anti-tachycardia pacing therapy and lifesaving defibrillations in one system, using a device as big as conventional, transvenous ICDs.
Reportedly, findings from the study were exhibited over a late-breaking session at the 40th Heart Rhythm Session.

Sources claimed that the pilot study, which denotes the first-in-human long-term use of investigational, first-generation system, exhibits that this system could be implanted without any major complications, and can effectively sense, defibrillate, and pace the heart.

Reportedly, the pilot study was conducted on 21 patients across four sites in Australia and New Zealand. Patients were assessed at implant, 2 weeks, 4 to 6 weeks, and 3 months post device’s implantation, and continue to be followed. As per investigators, the defibrillation tests were conducted on 19 patients, at the time of implant. The system effectively terminated induced ventricular arrhythmias in 17 patients, which is steady with previous clinical trials of existing ICDs. Moreover, the pacing capture was accomplished in over 95 percent of study patients. Among which, one individual suffered ventricular tachycardia outside the hospital premises, which was effectively diagnosed and treated through the EV ICD system, cited investigators.

For the record, through EV ICD systems, Medtronic aims to deliver the benefits of conventional, transvenous ICDs comprising anti-tachycardia pacing to tackle arrhythmias; lifesaving defibrillation therapy; post-shock pacing; and provisional back-up, bradycardia pacing to treat unusually slow heart rates. The EV ICD device is fixed in the left mid-axillary area underneath the left armpit, while the lead is positioned below the sternum or breastbone.

The EV ICD system is investigational globally and therefore, not permitted for sale or distribution, reported sources.

Source Credit: https://www.globenewswire.com/news-release/2019/05/11/1822165/0/en/Medtronic-Reveals-Results-of-First-In-Human-Study-for-Investigational-Extravascular-ICD-System.html



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Raspberry Pi opens its inaugural brick-and-mortar retail store
Raspberry Pi opens its inaugural brick-and-mortar retail store
By Saipriya Iyer

Raspberry Pi is one among the many online retailers that is expanding offline to gain more customers.

Raspberry Pi has reportedly opened its very first brick-and-mo...

Orchard Therapeutics to present clinical data for OTL-101 & OTL-102
Orchard Therapeutics to present clinical data for OTL-101 & OTL-102
By Saipriya Iyer

Biopharma major Orchard Therapeutics has reportedly made it to the front page for having announced details of oral and poster presentations for new clinical data. As per sources familiar with the knowledge of the matte...

Rutgers & Horizon plan to commercialize CRISPR base editing technology
Rutgers & Horizon plan to commercialize CRISPR base editing technology
By Saipriya Iyer

Horizon has also agreed to fund further research in base editing at the Rutgers University.

Horizon Discovery Group plc, one of the globally reputed gene editing in...